Professional Media briefs

Share this article:
London-based Future Science Group announced the launch of Diabetes Management, a new title focused on current therapeutics and patient compliance with respect to diabetes types 1 and 2. Jaakko Tuomilehto, MD, one of four associate editors, said in a statement that despite the several other journals covering diabetes, “it's obvious that there is a place and need for a new one, especially one that deals with the management of diabetes.”

Epocrates, a mobile drug reference provider, added Peter Brandt to its board of directors. Brandt is a former Pfizer exec, serving most recently as president of Pfizer's US pharmaceuticals operations. In his new role, Brandt will help to guide the strategic direction of Epocrates' interactive services.

Quadrant HealthCom promoted Dianne Reynolds to publisher of The Women's Health Alliance, which includes QHC titles OBG Management and The Female Patient. Reynolds succeeds Margo Ullmann as publisher; Ullmann was promoted to group publisher of The Women's Health Alliance. Ullmann and Reynolds will continue to cross-sell between the two Alliance titles to provide a “more efficient and effective sales management team,” according to a statement.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?